echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The generics market is in a big shuffle, with more than 50% of the varieties likely to disappear

    The generics market is in a big shuffle, with more than 50% of the varieties likely to disappear

    • Last Update: 2020-11-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    "Pharmaceutical network industry dynamics" recently, the State Drug Administration issued a notice that decided to cancel the injection of the forefront, sodium glazate eye drops, amosicillin capsules, cephalosporatin capsules, cephalosporine particles and pig immunoglobulin oral solution and other 78 drug registration certificates.
    generic drug market reshuffle, more than 50% of the varieties or will disappear the author comb found that in this batch of 78 drugs, 74 drugs according to the application to cancel, 3 do not re-register and 1 legally cancelled.
    Of these, two pharmaceutical companies have written off a larger number of drug approvals, namely, six Anhuayuan Pharmaceuticals wrote off the number of drug approvals reached 21, the State Pharmaceutical Group Refined Party (Anhui) Pharmaceuticals wrote off the number of drug approvals reached 42.
    fact, it is not uncommon for pharmaceutical companies to voluntarily write off drugs.
    can say that this has become a common phenomenon in the industry.
    can be seen from the many announcements of the Drug Administration, more and more small and medium-sized pharmaceutical enterprises are seeking to withdraw from the market, began to cancel drug production licenses, cancel business licenses, transfer drug approval, plant transfer as a whole.
    it is worth mentioning that in recent years, drug companies write-off information, more and more large varieties, common drugs are being accelerated to give up.
    this, the industry believes that the application for write-off of these drugs is mainly excessive duplication, in the current emphasis on "innovation" and "generic drug consistency evaluation" in the reform process, it is inevitable to be eliminated by the market.
    data show that there are a large number of over-repeated varieties in China.
    according to china's over-repeated drug tips released by the State Drug Administration in early 2018, there are nearly 300 varieties approved for more than 20 varieties of the same variety in China.
    , the number of approvals, the number of enterprises, the number of approvals in the last three years and the number of enterprises in the sale of approvals are more than 120 varieties there are 10.
    number of approvals for varieties such as methazole, glucose and vitamin C was more than 1000.
    To this written-off "injection with the forefront of the Dil" as an example, only domestic drugs have 41 drug approvals, and the number of vitamin C approvals even as high as 2378, the degree of repetition is shnoty.
    , in order to eliminate some low-level highly repeatable varieties, in recent years the state began to introduce a series of policies to shuffle the generic drug market, in which consistent evaluation can be said to have had a significant impact on the entire pharmaceutical market.
    , according to incomplete statistics, since 2016, at least 300 varieties have voluntarily applied for revocation.
    analysts pointed out that with the consistent evaluation and other policies landing, there will be more and more generic varieties out of the market in the future.
    , at least half of the 150,000 generic approvals are expected to disappear.
    , generics, especially those that have not passed a consistent evaluation, have accelerated so far this year.
    April 13, the Beijing Pharmaceutical Harvesting Platform issued a notice, which called for the suspension of 843 drugs in the country's procurement varieties that did not pass the consistent evaluation.
    April 10, the Shanghai Pharmaceutical Harvesting Platform announced that it would no longer purchase drugs that failed to pass the consistent evaluation by evaluating more than three enterprises through consistency evaluation, and also made it clear that the procurement and settlement of the corresponding drugs would also expire simultaneously on April 20.
    The industry believes that Beijing, Shanghai are the top three procurement amount of the market, its action will undoubtedly become the national market "benchmark", under the pressure of these policies, the phase-out process of the generic drug market nearly accelerated.
    In general, a series of policies in the pharmaceutical reform is constantly squeezing out the gray profit part of the previous circulation link, although leaving a reasonable profit of generic drugs, but want to make a lot of money through the sales channels of the day will not have, if enterprises want to make money, there are two options, either expand the scale, improve quality, control costs, improve supply management level, quality and cost control to win, or increase investment in research and development of new drugs, innovation to win.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.